JP Morgan Chase
NMRA icon

JP Morgan Chase’s Neumora Therapeutics NMRA Stock Holding History

JP Morgan Chase’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,800
Closed -$72.1K – 7605
2024
Q4 		$72.1K Buy
+6,800
New +$81.5K ﹤0.01% 5884

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

JP Morgan Chase's NMRA Position: Q1 2026 in Review

JP Morgan Chase increased its Neumora Therapeutics (NMRA) stake by 2,511% in Q1 2026, buying an estimated $683K and bringing the position to 274,103 shares worth $529K. The position accounts for ﹤0.01% of the portfolio, ranked #4955.

JP Morgan Chase first reported a position in NMRA in Q4 2023 and has held it in 10 quarters since. The position peaked at $14.8M in Q4 2024. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • JP Morgan Chase held 274,103 shares of Neumora Therapeutics worth $529K as of Q1 2026.
  • JP Morgan Chase bought 263,606 Neumora Therapeutics shares in Q1 2026, an estimated $683K.
  • Neumora Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4955 holding.
  • JP Morgan Chase first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • JP Morgan Chase's Neumora Therapeutics position peaked at $14.8M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.